{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T06:28:41Z","timestamp":1793946521722,"version":"4.8.0"},"reference-count":139,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.eclinm.2026.103895","type":"journal-article","created":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T22:54:49Z","timestamp":1781564089000},"page":"103895","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Antibody drug conjugates in gynaecological cancers: navigating between opportunities and challenges"],"prefix":"10.1016","volume":"97","author":[{"given":"Esteban","family":"Ciliberti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Nerone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenza","family":"Ricco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Ming","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik","family":"Marm\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiana","family":"Sessa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle Ray","family":"Coquard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen N.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0602-8667","authenticated-orcid":false,"given":"Ilaria","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.eclinm.2026.103895_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.eclinm.2026.103895_bib2","doi-asserted-by":"crossref","DOI":"10.7189\/jogh.14.04155","article-title":"Global burden of gynaecological cancers in 2022 and projections to 2050","volume":"14","author":"Zhu","year":"2024","journal-title":"J Glob Health"},{"issue":"8","key":"10.1016\/j.eclinm.2026.103895_bib3","doi-asserted-by":"crossref","first-page":"e423","DOI":"10.1016\/S1470-2045(25)00167-6","article-title":"ESGO-ESTRO-ESP guidelines for the management of patients with endometrial carcinoma: update 2025","volume":"26","author":"Concin","year":"2025","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.eclinm.2026.103895_bib4","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1136\/ijgc-2023-004429","article-title":"ESGO\/ESTRO\/ESP Guidelines for the management of patients with cervical cancer - update 2023","volume":"33","author":"Cibula","year":"2023","journal-title":"Int J Gynecol Cancer"},{"issue":"10","key":"10.1016\/j.eclinm.2026.103895_bib5","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.annonc.2023.07.011","article-title":"Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Gonzalez-Martin","year":"2023","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.eclinm.2026.103895_bib6","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1158\/2159-8290.CD-24-0708","article-title":"The journey of antibody-drug conjugates: lessons learned from 40 years of development","volume":"14","author":"Colombo","year":"2024","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.eclinm.2026.103895_bib7","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s13238-016-0323-0","article-title":"Antibody-drug conjugates: recent advances in conjugation and linker chemistries","volume":"9","author":"Tsuchikama","year":"2018","journal-title":"Protein Cell"},{"issue":"8","key":"10.1016\/j.eclinm.2026.103895_bib8","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/s41571-023-00783-w","article-title":"Optimizing the safety of antibody-drug conjugates for patients with solid tumours","volume":"20","author":"Tarantino","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.eclinm.2026.103895_bib9","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.2147\/DDDT.S135571","article-title":"Intracellular trafficking of new anticancer therapeutics: antibody-drug conjugates","volume":"11","author":"Kalim","year":"2017","journal-title":"Drug Des Devel Ther"},{"issue":"6","key":"10.1016\/j.eclinm.2026.103895_bib10","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1093\/jnci\/djz035","article-title":"Antibody-drug conjugate-based therapeutics: state of the science","volume":"111","author":"Birrer","year":"2019","journal-title":"J Natl Cancer Inst"},{"issue":"12","key":"10.1016\/j.eclinm.2026.103895_bib11","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1038\/bjc.2017.367","article-title":"Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required?","volume":"117","author":"Staudacher","year":"2017","journal-title":"Br J Cancer"},{"issue":"5","key":"10.1016\/j.eclinm.2026.103895_bib12","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1021\/acs.bioconjchem.7b00062","article-title":"Effects of drug-antibody ratio on pharmacokinetics, biodistribution, efficacy, and tolerability of antibody-maytansinoid conjugates","volume":"28","author":"Sun","year":"2017","journal-title":"Bioconjug Chem"},{"issue":"2","key":"10.1016\/j.eclinm.2026.103895_bib13","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.ygyno.2017.08.015","article-title":"Characterization of folate receptor alpha (FRalpha) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: a phase I expansion study of the FRalpha-targeting antibody-drug conjugate mirvetuximab soravtansine","volume":"147","author":"Martin","year":"2017","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.eclinm.2026.103895_bib14","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/852748","article-title":"Human epidermal growth factor receptor 2 (HER2) in cancers: overexpression and therapeutic implications","volume":"2014","author":"Iqbal","year":"2014","journal-title":"Mol Biol Int"},{"issue":"4","key":"10.1016\/j.eclinm.2026.103895_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2023.188902","article-title":"Targeting Trop-2 in cancer: recent research progress and clinical application","volume":"1878","author":"Qiu","year":"2023","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"7","key":"10.1016\/j.eclinm.2026.103895_bib16","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1002\/1878-0261.12947","article-title":"CDH6-activated alphaIIbbeta3 crosstalks with alpha2beta1 to trigger cellular adhesion and invasion in metastatic ovarian and renal cancers","volume":"15","author":"Bartolome","year":"2021","journal-title":"Mol Oncol"},{"key":"10.1016\/j.eclinm.2026.103895_bib17","doi-asserted-by":"crossref","first-page":"S116","DOI":"10.1016\/S0090-8258(22)01432-9","article-title":"Clinical significance of cadherin-6 expression in primary and recurrent epithelial ovarian cancer and its association with outcomes: a potential therapeutic target for epithelial ovarian cancer (206)","volume":"166","author":"Shintani","year":"2022","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.eclinm.2026.103895_bib18","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1186\/1746-1596-8-190","article-title":"Clinicopathologic significance of claudin-6, occludin, and matrix metalloproteinases -2 expression in ovarian carcinoma","volume":"8","author":"Wang","year":"2013","journal-title":"Diagn Pathol"},{"issue":"10","key":"10.1016\/j.eclinm.2026.103895_bib19","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12102748","article-title":"Prognostic significance of aberrant Claudin-6 expression in endometrial cancer","volume":"12","author":"Kojima","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"24","key":"10.1016\/j.eclinm.2026.103895_bib20","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222413416","article-title":"CLDN6: from traditional barrier function to emerging roles in cancers","volume":"22","author":"Qu","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"10","key":"10.1016\/j.eclinm.2026.103895_bib21","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007572","article-title":"SGN-B7H4V, an investigational vedotin ADC directed to the immune checkpoint ligand B7-H4, shows promising activity in preclinical models","volume":"11","author":"Gray","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.eclinm.2026.103895_bib22","doi-asserted-by":"crossref","first-page":"4275","DOI":"10.2147\/OTT.S318082","article-title":"Expression of B7-H3 correlates with PD-L1 and poor prognosis in patients with cervical cancer","volume":"14","author":"Zhang","year":"2021","journal-title":"OncoTargets Ther"},{"issue":"2","key":"10.1016\/j.eclinm.2026.103895_bib23","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s40291-017-0255-2","article-title":"Correlation between tumor mesothelin expression and serum mesothelin in patients with epithelial ovarian carcinoma: a potential noninvasive biomarker for mesothelin-targeted therapy","volume":"21","author":"Hanaoka","year":"2017","journal-title":"Mol Diagn Ther"},{"issue":"6","key":"10.1016\/j.eclinm.2026.103895_bib24","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1158\/1535-7163.MCT-13-0926","article-title":"Anetumab ravtansine: a novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect","volume":"13","author":"Golfier","year":"2014","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.eclinm.2026.103895_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102489","article-title":"Targeting NaPi2b in ovarian cancer","volume":"112","author":"Banerjee","year":"2023","journal-title":"Cancer Treat Rev"},{"issue":"2","key":"10.1016\/j.eclinm.2026.103895_bib26","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1158\/1078-0432.CCR-18-3965","article-title":"Phase Ia Study of Anti-NaPi2b antibody-drug conjugate Lifastuzumab Vedotin DNIB0600A in patients with non-small cell lung cancer and platinum-resistant ovarian cancer","volume":"26","author":"Gerber","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.eclinm.2026.103895_bib27","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/j.ygyno.2024.07.039","article-title":"Efficacy and safety of 9MW2821, an antibody-drug conjugate targeting Nectin-4 monotherapy, in patients with recurrent or metastatic cervical cancer: a multicenter, open-label, phase I\/II study","volume":"190","author":"Yang","year":"2024","journal-title":"Gynecol Oncol"},{"issue":"5","key":"10.1016\/j.eclinm.2026.103895_bib28","first-page":"4075","article-title":"Expression of tissue factor in human cervical carcinoma tissue","volume":"16","author":"Zhao","year":"2018","journal-title":"Exp Ther Med"},{"issue":"4","key":"10.1016\/j.eclinm.2026.103895_bib29","first-page":"284","article-title":"Ovarian cancer statistics, 2018","volume":"68","author":"Torre","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.eclinm.2026.103895_bib30","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.semcancer.2021.03.031","article-title":"Revisiting antibody-drug conjugates and their predictive biomarkers in platinum-resistant ovarian cancer","volume":"77","author":"El Bairi","year":"2021","journal-title":"Semin Cancer Biol"},{"issue":"6","key":"10.1016\/j.eclinm.2026.103895_bib31","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.annonc.2021.02.017","article-title":"Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I","volume":"32","author":"Moore","year":"2021","journal-title":"Ann Oncol"},{"issue":"13","key":"10.1016\/j.eclinm.2026.103895_bib32","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1200\/JCO.22.01900","article-title":"Efficacy and safety of Mirvetuximab Soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression: results from the SORAYA Study","volume":"41","author":"Matulonis","year":"2023","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.eclinm.2026.103895_bib33","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1056\/NEJMoa2309169","article-title":"Mirvetuximab soravtansine in FRalpha-Positive, platinum-resistant ovarian cancer","volume":"389","author":"Moore","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2026.103895_bib34","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ygyno.2024.01.045","article-title":"Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha (FRalpha)-targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab in patients with platinum-sensitive ovarian cancer","volume":"185","author":"Richardson","year":"2024","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.eclinm.2026.103895_bib35","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.annonc.2024.11.011","article-title":"The efficacy and safety of mirvetuximab soravtansine in FRalpha-positive, third-line and later, recurrent platinum-sensitive ovarian cancer: the single-arm phase II PICCOLO trial","volume":"36","author":"Alvarez Secord","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eclinm.2026.103895_bib36","author":"Lee","year":"2025"},{"key":"10.1016\/j.eclinm.2026.103895_bib37","doi-asserted-by":"crossref","first-page":"S572","DOI":"10.1016\/j.annonc.2024.08.815","article-title":"Initial results from a first-in-human study of AZD5335, a folate receptor \u03b1 (FR\u03b1)-targeted antibody-drug conjugate, in patients (pts) with platinum-resistant recurrent ovarian cancer (PRROC)","volume":"35","author":"Shapira-Frommer","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eclinm.2026.103895_bib65","doi-asserted-by":"crossref","first-page":"S715","DOI":"10.1016\/j.annonc.2025.08.1707","article-title":"Results from the first-in-human phase I study of LY4170156, an antibody drug conjugate (ADC) targeting folate receptor alpha in recurrent platinum resistant high-grade serous ovarian cancer (HGSOC)","volume":"36","author":"Ray-Coquard","year":"2025","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.eclinm.2026.103895_bib39","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of Trastuzumab Deruxtecan in patients with HER2-Expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eclinm.2026.103895_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2024.08.782","article-title":"IBI354 (anti-HER2 antibody\u2013drug conjugate) in patients with advanced gynecological cancers: results from a phase I study","volume":"35","author":"Shu","year":"2024","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.eclinm.2026.103895_bib41","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12967-024-05985-z","article-title":"A phase Ia study of a novel anti-HER2 antibody-drug conjugate GQ1001 in patients with previously treated HER2 positive advanced solid tumors","volume":"23","author":"Zhou","year":"2025","journal-title":"J Transl Med"},{"key":"10.1016\/j.eclinm.2026.103895_bib42","doi-asserted-by":"crossref","first-page":"S547","DOI":"10.1016\/j.annonc.2024.08.776","article-title":"Datopotamab deruxtecan (Dato-DXd) in patients with endometrial (EC) or ovarian cancer (OC): results from the phase II TROPION-PanTumor03 study","volume":"35","author":"Oaknin","year":"2024","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.eclinm.2026.103895_bib43","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.annonc.2021.03.005","article-title":"Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I\/II IMMU-132-01 basket trial","volume":"32","author":"Bardia","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eclinm.2026.103895_bib44","article-title":"Safety and efficacy of sacituzumab tirumotecan (sac-TMT) in patients (pts) with previously treated advanced endometrial carcinoma (EC) and ovarian cancer (OC) from a phase II study","volume":"35","author":"Wang","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eclinm.2026.103895_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2024.08.779","article-title":"SHR-A1921 in platinum-resistant ovarian cancer (PROC): data from a first-in-human (FIH) phase I study","volume":"35","author":"Song","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eclinm.2026.103895_bib46","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ygyno.2025.03.061","article-title":"DB-1305\/BNT325, a novel trophoblast cell-surface antigen 2 antibody-drug conjugate, in patients with ovarian cancer: efficacy and safety data from a phase I\/II study","volume":"200","author":"Rubinstein","year":"2025","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.eclinm.2026.103895_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2023.09.1924","article-title":"Raludotatug deruxtecan (R-DXd; DS-6000) monotherapy in patients with previously treated ovarian cancer (OVC): subgroup analysis of a first-in-human phase I study","volume":"34","author":"Moore","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eclinm.2026.103895_bib48","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1016\/j.ygyno.2024.07.017","article-title":"Raludotatug deruxtecan monotherapy among patients with previously treated ovarian cancer: subgroup analysis of a first-in-human phase I study","volume":"190","author":"Moore","year":"2024","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.eclinm.2026.103895_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2024.08.783","article-title":"Phase I, two-part, multicenter first-in-human (FIH) study of TORL-1-23: a novel claudin 6 (CLDN6) targeting antibody drug conjugate (ADC) in patient with advanced solid tumors","volume":"35","author":"Konecny","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eclinm.2026.103895_bib50","doi-asserted-by":"crossref","first-page":"S485","DOI":"10.1016\/j.annonc.2024.08.673","article-title":"Initial results from a first-in-human study of the B7-H4-directed antibody-drug conjugate (ADC) AZD8205 (puxitatug samrotecan) in patients with advanced\/metastatic solid tumors","volume":"35","author":"Meric-Bernstam","year":"2024","journal-title":"Ann Oncol"},{"issue":"16_suppl","key":"10.1016\/j.eclinm.2026.103895_bib51","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1200\/JCO.2025.43.16_suppl.3009","article-title":"Initial phase 1 dose escalation data for emiltatug ledadotin (Emi-Le; XMT-1660)","volume":"43","author":"Hamilton","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eclinm.2026.103895_bib52","doi-asserted-by":"crossref","first-page":"S464","DOI":"10.1016\/j.annonc.2023.09.1846","article-title":"First-in-human study of SGN-B7H4V, a B7-H4-directed vedotin ADC, in patients with advanced solid tumors: preliminary results of a phase I study (SGNB7H4V-001)","volume":"34","author":"Perez","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eclinm.2026.103895_bib53","article-title":"First-in-human\/phase I trial of HS-20089, a B7-H4 ADC, in patients with advanced solid tumors","volume":"34","author":"Wu","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eclinm.2026.103895_bib54","series-title":"Presented at ESMO ASIA congress","article-title":"DB-1311\/BNT324 (a novel B7H3 ADC) in patients with advanced cervical cancer or platinum-resistant recurrent ovarian cancer","author":"Chang","year":"2025"},{"issue":"4","key":"10.1016\/j.eclinm.2026.103895_bib55","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1136\/ijgc-2022-003927","article-title":"Safety and activity of Anti-mesothelin antibody-drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion study","volume":"33","author":"Santin","year":"2023","journal-title":"Int J Gynecol Cancer"},{"issue":"6","key":"10.1016\/j.eclinm.2026.103895_bib56","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1158\/1078-0432.CCR-24-3128","article-title":"Randomized phase II study of bevacizumab with weekly anetumab ravtansine or weekly paclitaxel in platinum-resistant\/refractory high-grade ovarian cancer (NCI Trial)","volume":"31","author":"Alqaisi","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"15_suppl","key":"10.1016\/j.eclinm.2026.103895_bib73","doi-asserted-by":"crossref","first-page":"5569","DOI":"10.1200\/JCO.2016.34.15_suppl.5569","article-title":"A randomized, open-label, phase II study of anti-NaPi2b antibody-drug conjugate (ADC) lifastuzumab (Lifa) vedotin (DNIB0600A) compared to pegylated liposomal doxorubicin (PLD) in patients (pts) with platinum-resistant ovarian cancer (PROC)","volume":"34","author":"Banerjee","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eclinm.2026.103895_bib58","article-title":"UPLIFT (ENGOT-OV67\/GOG-3048): results from the phase II trial of upifitamab rilsodotin (UpRi; XMT-1536), a NaPi2b-directed dolaflexin antibody-drug conjugate in platinum-resistant ovarian cancer","volume":"190","author":"Richardson","year":"2024","journal-title":"Gynecol Oncol"},{"issue":"8","key":"10.1016\/j.eclinm.2026.103895_bib59","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1136\/ijgc-2024-005401","article-title":"Mirvetuximab soravtansine in folate receptor alpha (FRalpha)-high platinum-resistant ovarian cancer: final overall survival and post hoc sequence of therapy subgroup results from the SORAYA trial","volume":"34","author":"Coleman","year":"2024","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.eclinm.2026.103895_bib140","series-title":"Presented at: American Society of Clinical Oncology Annual Meeting","article-title":"Mirvetuximab soravtansine, a folate receptor \u03b1-targeting antibody drug conjugate, in combination with bevacizumab in patients with platinum agnostic ovarian cancer: final analysis","author":"O\u2019Malley","year":"2021"},{"issue":"32","key":"10.1016\/j.eclinm.2026.103895_bib60","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1080\/14796694.2024.2372241","article-title":"Maintenance with mirvetuximab soravtansine plus bevacizumab vs bevacizumab in FRalpha-high platinum-sensitive ovarian cancer","volume":"20","author":"O'Malley","year":"2024","journal-title":"Future Oncol"},{"issue":"suppl_5","key":"10.1016\/j.eclinm.2026.103895_bib61","first-page":"1","volume":"9","author":"Banerjee","year":"2024","journal-title":"Ann Oncol"},{"issue":"16_suppl","key":"10.1016\/j.eclinm.2026.103895_bib62","doi-asserted-by":"crossref","first-page":"5508","DOI":"10.1200\/JCO.2023.41.16_suppl.5508","volume":"41","author":"Oaknin","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eclinm.2026.103895_bib63","series-title":"Efficacy and safety of luveltamab tazevibulin in patients with recurrent platinum-resistant ovarian cancer: results from the dose-optimization stage of the REFR\u03b1ME-O1 (GOG-3086, ENGOT-79OV, and APGOT-OV9) phase 2\/3 study","author":"Lee","year":"2025"},{"issue":"S550","key":"10.1016\/j.eclinm.2026.103895_bib64","article-title":"A phase I\/II study of rinatabart sesutecan (Rina-S) in patients with advanced ovarian or endometrial cancer","volume":"35","author":"Lee","year":"2024","journal-title":"Ann Oncol"},{"issue":"suppl_2","key":"10.1016\/j.eclinm.2026.103895_bib38","first-page":"S718","article-title":"First-in-human study of AZD5335, a folate receptor \u03b1 (FR\u03b1)-targeted antibody-drug conjugate, in patients with platinum-resistant recurrent ovarian cancer","volume":"36","author":"Oaknin","year":"2025","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.eclinm.2026.103895_bib66","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/bjc.1996.53","article-title":"The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer","volume":"73","author":"Bartlett","year":"1996","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.eclinm.2026.103895_bib67","doi-asserted-by":"crossref","first-page":"7992","DOI":"10.1038\/s41598-024-57515-y","article-title":"Human epidermal growth factor receptor-2 expression and subsequent dynamic changes in patients with ovarian cancer","volume":"14","author":"Kim","year":"2024","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.eclinm.2026.103895_bib68","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ygyno.2017.04.023","article-title":"SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2\/Neu expression","volume":"146","author":"Menderes","year":"2017","journal-title":"Gynecol Oncol"},{"issue":"suppl_2","key":"10.1016\/j.eclinm.2026.103895_bib69","first-page":"S544","article-title":"IBI354 (anti-HER2 antibody-drug conjugate [ADC]) in patients (pts) with advanced gynecological cancers (Gynecol C): results from a phase I study","volume":"35","author":"Shu","year":"2024","journal-title":"Ann Oncol"},{"issue":"16_suppl","key":"10.1016\/j.eclinm.2026.103895_bib70","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.1200\/JCO.2023.41.16_suppl.3023","article-title":"Safety and efficacy of DB-1303 in patients with advanced\/metastatic solid tumors: a multicenter, open-label, first-in-human, phase 1\/2a study","volume":"41","author":"Moore","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.eclinm.2026.103895_bib71","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13045-025-01705-2","article-title":"Results of a phase 1\/2 study of sacituzumab tirumotecan in patients with unresectable locally advanced or metastatic solid tumors refractory to standard therapies","volume":"18","author":"Ouyang","year":"2025","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.eclinm.2026.103895_bib57","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.annonc.2025.09.054","article-title":"Raludotatug deruxtecan (R-DXd) in patients (pts) with platinum-resistant ovarian cancer (PROC): primary analysis of the phase II dose-optimization part of REJOICE-Ovarian01","volume":"36","author":"Ray-Coquard","year":"2025","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.eclinm.2026.103895_bib72","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.ygyno.2020.05.039","article-title":"Phase 1b study of anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) in patients with platinum-sensitive recurrent ovarian cancer","volume":"158","author":"Moore","year":"2020","journal-title":"Gynecol Oncol"},{"issue":"16_suppl","key":"10.1016\/j.eclinm.2026.103895_bib74","doi-asserted-by":"crossref","first-page":"TPS5614","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS5614","article-title":"UP-NEXT (GOG-3049\/ENGOT-Ov71-NSGO-CTU): a study of upitifamab rilsodotin (UpRi), a NaPi2b-directed antibody drug conjugate (ADC), in platinum-sensitive recurrent ovarian cancer","volume":"41","author":"Richardson","year":"2023","journal-title":"J Clin Oncol"},{"issue":"suppl_2","key":"10.1016\/j.eclinm.2026.103895_bib75","first-page":"S1","article-title":"NAPISTAR 1-01: a phase I dose escalation study of TUB-040, a novel NaPi2b-targeting exatecan antibody-drug conjugate (ADC) in patients with platinum-resistant ovarian (PROC) high grade serous carcinoma (HGSC)","volume":"36","author":"Gonzalez-Martin","year":"2025","journal-title":"Ann Oncol"},{"issue":"16","key":"10.1016\/j.eclinm.2026.103895_bib76","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1200\/JCO.19.02085","article-title":"First-in-human, multicenter, phase I dose-escalation and expansion study of anti-mesothelin antibody-drug conjugate anetumab ravtansine in advanced or metastatic solid tumors","volume":"38","author":"Hassan","year":"2020","journal-title":"J Clin Oncol"},{"issue":"8_Supplement_2","key":"10.1016\/j.eclinm.2026.103895_bib77","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2025-CT188","article-title":"BEHOLD-1: a phase 1 dose escalation study of GSK5733584, a B7-H4-Targeted antibody-drug conjugate, in patients with advanced solid tumors, including dose expansion in patients with endometrial and platinum-resistant ovarian cancer","volume":"85","author":"McKean","year":"2025","journal-title":"Cancer Res"},{"issue":"7_Supplement","key":"10.1016\/j.eclinm.2026.103895_bib79","doi-asserted-by":"crossref","first-page":"CT008","DOI":"10.1158\/1538-7445.AM2024-CT008","article-title":"A phase 2, two-stage study of mirvetuximab soravtansine (IMGN853) in combination with pembrolizumab in patients with microsatellite stable (MSS) recurrent or persistent endometrial cancer [abstract]","volume":"84","author":"Porter Rlx","year":"2024","journal-title":"Cancer Res"},{"key":"10.1016\/j.eclinm.2026.103895_bib80","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2023.09.1920","article-title":"Luveltamab tazevibulin (STRO-002), an anti-folate receptor alpha (FolR\u03b1) antibody drug conjugate (ADC), demonstrates clinical activity in recurrent\/progressive epithelial endometrial cancer (EEC): STRO-002-GM1 phase I dose expansion","volume":"34","author":"Pothuri","year":"2023","journal-title":"Ann Oncol"},{"issue":"16_suppl","key":"10.1016\/j.eclinm.2026.103895_bib81","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.1200\/JCO.2025.43.16_suppl.3039","article-title":"Rinatabart sesutecan (Rina-S) for patients with advanced endometrial cancer: first disclosure from dose expansion cohort B2 of the GCT1184-01 study","volume":"43","author":"Winer","year":"2025","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.eclinm.2026.103895_bib82","doi-asserted-by":"crossref","first-page":"3905","DOI":"10.1158\/1078-0432.CCR-20-4740","article-title":"First-in-Human phase 1 Study of MORAb-202, an antibody-drug conjugate comprising farletuzumab linked to eribulin mesylate, in patients with folate receptor-alpha-positive advanced solid tumors","volume":"27","author":"Shimizu","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eclinm.2026.103895_bib83","doi-asserted-by":"crossref","first-page":"A9","DOI":"10.1136\/ijgc-2023-ESGO.14","article-title":"DB-1303, a HER2-targeting ADC, for patients with advanced\/metastatic endometrial cancer: preliminary clinical results from an ongoing phase 1\/2a trial (NCT05150691)","volume":"33","author":"Moore","year":"2023","journal-title":"Int J Gynecol Cancer"},{"issue":"29","key":"10.1016\/j.eclinm.2026.103895_bib84","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1200\/JCO.23.02767","article-title":"Efficacy and safety of sacituzumab govitecan in patients with advanced solid tumors (TROPiCS-03): analysis in patients with advanced endometrial cancer","volume":"42","author":"Santin","year":"2024","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10.1016\/j.eclinm.2026.103895_bib85","doi-asserted-by":"crossref","first-page":"5599","DOI":"10.1200\/JCO.2023.41.16_suppl.5599","article-title":"Preliminary results of a phase II trial with sacituzumab govitecan-hziy in patients with recurrent endometrial carcinoma overexpressing Trop-2","volume":"41","author":"Santin","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eclinm.2026.103895_bib86","series-title":"Emiltatug ledadotin generates positive initial data in advanced\/metastatic solid tumors","author":"Doherty","year":"2025"},{"key":"10.1016\/j.eclinm.2026.103895_bib87","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ygyno.2025.02.005","article-title":"HER2 expression in a molecularly defined cohort of endometrial cancer patients: the SPECTRUM study","volume":"194","author":"Cortes-Salgado","year":"2025","journal-title":"Gynecol Oncol"},{"issue":"16","key":"10.1016\/j.eclinm.2026.103895_bib88","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1002\/cncr.30736","article-title":"Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor alpha-targeting antibody-drug conjugate, in patients with solid tumors","volume":"123","author":"Moore","year":"2017","journal-title":"Cancer"},{"issue":"16_suppl","key":"10.1016\/j.eclinm.2026.103895_bib89","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.1200\/JCO.2025.43.16_suppl.3039","article-title":"Rinatabart sesutecan (Rina-S) for patients with advanced endometrial cancer: first disclosure from dose expansion cohort B2 of the GTC1184-01 study","volume":"43","author":"Winer","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eclinm.2026.103895_bib90","article-title":"XMT-1660: a phase I, first-in-human trial of a B7-H4-directed dolasynthen antibody-drug conjugate in ovarian, endometrial, and breast cancers","volume":"190","author":"Rea","year":"2024","journal-title":"Gynecol Oncol"},{"issue":"36","key":"10.1016\/j.eclinm.2026.103895_bib91","doi-asserted-by":"crossref","first-page":"5505","DOI":"10.1200\/JCO.23.00914","article-title":"First-Line pembrolizumab + chemotherapy versus placebo + chemotherapy for persistent, recurrent, or metastatic cervical cancer: final overall survival results of KEYNOTE-826","volume":"41","author":"Monk","year":"2023","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.eclinm.2026.103895_bib92","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100579","article-title":"Recurrent or primary metastatic cervical cancer: current and future treatments","volume":"7","author":"Gennigens","year":"2022","journal-title":"ESMO Open"},{"issue":"1","key":"10.1016\/j.eclinm.2026.103895_bib93","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1056\/NEJMoa2313811","article-title":"Tisotumab vedotin as second- or third-line therapy for recurrent cervical cancer","volume":"391","author":"Vergote","year":"2024","journal-title":"N Engl J Med"},{"issue":"36","key":"10.1016\/j.eclinm.2026.103895_bib94","doi-asserted-by":"crossref","first-page":"5536","DOI":"10.1200\/JCO.23.00720","article-title":"Tisotumab vedotin in combination with Carboplatin, pembrolizumab, or Bevacizumab in recurrent or metastatic cervical cancer: results from the innovaTV 205\/GOG-3024\/ENGOT-cx8 study","volume":"41","author":"Vergote","year":"2023","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.eclinm.2026.103895_bib95","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1470-2045(21)00056-5","article-title":"Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204\/GOG-3023\/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Coleman","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eclinm.2026.103895_bib96","doi-asserted-by":"crossref","first-page":"5528","DOI":"10.1200\/JCO.2024.42.16_suppl.5528","article-title":"Evaluation of the effectiveness and safety of disitamab vedotin in HER2-expressing 2L recurrent or metastatic cervical cancer (r\/mCC): interim results of RC48-C018","volume":"42","author":"Yuan","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eclinm.2026.103895_bib97","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105347","article-title":"2O Sacituzumab govitecan (SG) for Chinese patients (Pts) with recurrent\/metastatic (R\/M) cervical cancer (CC): results from the EVER-132-003 basket study","volume":"10","author":"An","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.eclinm.2026.103895_bib98","doi-asserted-by":"crossref","DOI":"10.1038\/srep33658","article-title":"Impact of TROP2 expression on prognosis in solid tumors: a systematic review and meta-analysis","volume":"6","author":"Zeng","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.eclinm.2026.103895_bib99","first-page":"S548","article-title":"Efficacy and safety of sacituzumab tirumotecan (sac-TMT) plus pembrolizumab in patients with recurrent or metastatic cervical cancer","volume":"35","author":"Wang","year":"2024","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.eclinm.2026.103895_bib100","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.annonc.2025.04.009","article-title":"Bulumtatug Fuvedotin (BFv, 9MW2821), a next-generation Nectin-4 targeting antibody-drug conjugate, in patients with advanced solid tumors: a first-in-human, open-label, multicenter, phase I\/II study","volume":"36","author":"Zhang","year":"2025","journal-title":"Ann Oncol"},{"issue":"16_suppl","key":"10.1016\/j.eclinm.2026.103895_bib101","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1200\/JCO.2025.43.16_suppl.3018","article-title":"Preliminary results from a first-in-human phase 1 dose escalation trial of ADRX-0706, a next generation Nectin-4 ADC, in subjects with advanced solid tumors","volume":"43","author":"Drakaki","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eclinm.2026.103895_bib102","doi-asserted-by":"crossref","first-page":"S768","DOI":"10.1016\/j.annonc.2025.08.1802","article-title":"Tisotumab vedotin plus carboplatin or pembrolizumab in recurrent or metastatic cervical cancer: 5-year results from the innovaTV 205\/GOG-3024\/ENGOT-cx8 study","volume":"36","author":"Monk","year":"2025","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.eclinm.2026.103895_bib103","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/s41598-020-58009-3","article-title":"Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan","volume":"10","author":"Zeybek","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.eclinm.2026.103895_bib104","article-title":"Efficacy and safety of sacituzumab tirumotecan (Sac-TMT) monotherapy in advanced\/metastatic cervical cancer: results from a phase I\/II study (MK-2870-001\/KL264-01)","volume":"36","author":"Wang","year":"2025","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.eclinm.2026.103895_bib105","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1158\/1078-0432.CCR-23-2566","article-title":"TROP2 is associated with primary resistance to immune checkpoint inhibition in patients with advanced non-small cell lung cancer","volume":"30","author":"Bessede","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.eclinm.2026.103895_bib106","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.62347\/NHFJ1535","article-title":"The complex interplay of TROP2 and PD-L1 in immune regulation and drug resistance in lung cancer","volume":"15","author":"Yang","year":"2025","journal-title":"Am J Cancer Res"},{"issue":"9","key":"10.1016\/j.eclinm.2026.103895_bib107","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0257976","article-title":"Prevalence of HER2 overexpression and amplification in cervical cancer: a systematic review and meta-analysis","volume":"16","author":"Itkin","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.eclinm.2026.103895_bib108","article-title":"A phase I\/II multicenter, first-in-human study of DB-1311\/BNT324 (a novel B7H3 ADC) in patients with advanced solid tumors","volume":"35","author":"Cheng","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eclinm.2026.103895_bib109","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2024.102867","article-title":"Practical clinical management of ocular adverse events related to Antibody-Drug Conjugates in gynaecological malignancies","volume":"134","author":"Bouguerra Zina","year":"2025","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.eclinm.2026.103895_bib110","series-title":"Poster PS5-03-05: Presented at ESMO 2025 Congress","author":"Traina","year":"2025"},{"issue":"8","key":"10.1016\/j.eclinm.2026.103895_bib111","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1200\/OP.23.00097","article-title":"Detecting and managing T-DXd-Related interstitial lung disease: the five \u201cS\u201d rules","volume":"19","author":"Tarantino","year":"2023","journal-title":"JCO Oncol Pract"},{"issue":"9","key":"10.1016\/j.eclinm.2026.103895_bib112","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2025.101997","article-title":"Oral mucositis associated with antibody-drug conjugates in gynecologic oncology: strategies for prevention and treatment","volume":"35","author":"Lightfoot","year":"2025","journal-title":"Int J Gynecol Cancer"},{"issue":"3","key":"10.1016\/j.eclinm.2026.103895_bib113","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK_431766","article-title":"Unlocking the potential: biomarkers of response to antibody-drug conjugates","volume":"44","author":"Ascione","year":"2024","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"10","key":"10.1016\/j.eclinm.2026.103895_bib114","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15102664","article-title":"HER2 intratumoral heterogeneity in breast cancer, an evolving concept","volume":"15","author":"Hou","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.eclinm.2026.103895_bib115","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41523-023-00610-6","article-title":"Molecular imaging predicts lack of T-DM1 response in advanced HER2-positive breast cancer (final results of ZEPHIR trial)","volume":"10","author":"Mileva","year":"2024","journal-title":"NPJ Breast Cancer"},{"issue":"11","key":"10.1016\/j.eclinm.2026.103895_bib116","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2023.100299","article-title":"HER2 genetic intratumor heterogeneity is associated with resistance to Trastuzumab and Trastuzumab emtansine therapy in recurrent high-grade endometrial cancer","volume":"36","author":"Shen","year":"2023","journal-title":"Mod Pathol"},{"key":"10.1016\/j.eclinm.2026.103895_bib117","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115522","article-title":"Antibody drug conjugate targets are highly differentially expressed across the major types of ovarian cancer","volume":"224","author":"Porter","year":"2025","journal-title":"Eur J Cancer"},{"issue":"10","key":"10.1016\/j.eclinm.2026.103895_bib118","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1158\/1078-0432.CCR-24-2771","article-title":"TOP1 mutations and cross-resistance to antibody-drug conjugates in patients with metastatic breast cancer","volume":"31","author":"Abelman","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.eclinm.2026.103895_bib119","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105330","article-title":"Outcomes with trastuzumab deruxtecan by biomarker status, line of treatment and prior receipt of sacituzumab govitecan in a large real-world database of patients with metastatic breast cancer","volume":"10","author":"Tarantino","year":"2025","journal-title":"ESMO Open"},{"issue":"4","key":"10.1016\/j.eclinm.2026.103895_bib120","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/s41416-024-02766-9","article-title":"Efficacy of administration sequence: Sacituzumab Govitecan and Trastuzumab Deruxtecan in HER2-low metastatic breast cancer","volume":"131","author":"Poumeaud","year":"2024","journal-title":"Br J Cancer"},{"issue":"16_suppl","key":"10.1016\/j.eclinm.2026.103895_bib121","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1200\/JCO.2025.43.16_suppl.1053","article-title":"Antibody drug conjugates treatment response score (ADC TRS) for sequencing trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) in advanced breast cancer (aBC)","volume":"43","author":"Cani","year":"2025","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.eclinm.2026.103895_bib122","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1097\/CCO.0000000000001087","article-title":"Antibody-drug conjugates in metastatic breast cancer: sequencing, combinations and resistances","volume":"36","author":"Guidi","year":"2024","journal-title":"Curr Opin Oncol"},{"issue":"1","key":"10.1016\/j.eclinm.2026.103895_bib123","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s11912-024-01628-0","article-title":"Antibody-Drug conjugates in breast cancer: the road towards biologically-informed selection and sequencing","volume":"27","author":"O'Meara","year":"2025","journal-title":"Curr Oncol Rep"},{"issue":"4","key":"10.1016\/j.eclinm.2026.103895_bib124","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15041278","article-title":"Mechanisms of resistance to antibody-drug conjugates","volume":"15","author":"Abelman","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.eclinm.2026.103895_bib125","doi-asserted-by":"crossref","first-page":"28","DOI":"10.21037\/tbcr-23-38","article-title":"New-generation technologies for spatial tissue analysis, indispensable tools for deciphering intratumor heterogeneity in the development of antibody-drug conjugates and radio-immunoconjugates for cancer treatment","volume":"4","author":"Radosevic-Robin","year":"2023","journal-title":"Transl Breast Cancer Res"},{"issue":"10","key":"10.1016\/j.eclinm.2026.103895_bib126","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1158\/2159-8290.CD-21-0702","article-title":"Parallel genomic alterations of antigen and payload targets mediate Polyclonal acquired clinical resistance to Sacituzumab Govitecan in triple-negative breast cancer","volume":"11","author":"Coates","year":"2021","journal-title":"Cancer Discov"},{"issue":"17","key":"10.1016\/j.eclinm.2026.103895_bib127","doi-asserted-by":"crossref","first-page":"4639","DOI":"10.1158\/0008-5472.CAN-16-3127","article-title":"Resistance to the antibody-drug conjugate T-DM1 is based in a reduction in lysosomal proteolytic activity","volume":"77","author":"Rios-Luci","year":"2017","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.eclinm.2026.103895_bib128","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-023-01509-2","article-title":"The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors","volume":"17","author":"Wei","year":"2024","journal-title":"J Hematol Oncol"},{"issue":"3","key":"10.1016\/j.eclinm.2026.103895_bib129","doi-asserted-by":"crossref","first-page":"714","DOI":"10.37349\/etat.2024.00243","article-title":"Antibody-drug conjugates combinations in cancer treatment","volume":"5","author":"Pretelli","year":"2024","journal-title":"Explor Target Antitumor Ther"},{"key":"10.1016\/j.eclinm.2026.103895_bib130","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ygyno.2025.06.016","article-title":"Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRalpha)-targeting antibody-drug conjugate (ADC), in combination with pembrolizumab in patients with platinum-resistant ovarian cancer","volume":"200","author":"Matulonis","year":"2025","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.eclinm.2026.103895_bib131","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105253","article-title":"127TiP an open-label, randomized, multicenter, phase III study of trastuzumab deruxtecan (T-DXd) with bevacizumab (BEV) vs BEV monotherapy as first-line (1L) maintenance therapy in HER2-expressing ovarian cancer: Destiny-ovarian01 (DO 01)","volume":"10","author":"Gonz\u00e1lez-Mart\u00edn","year":"2025","journal-title":"ESMO Open"},{"issue":"2","key":"10.1016\/j.eclinm.2026.103895_bib132","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.annonc.2024.10.828","article-title":"Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1\/ENGOT-ov25 trial","volume":"36","author":"Harter","year":"2025","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.eclinm.2026.103895_bib133","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.annonc.2023.05.005","article-title":"Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1\/ENGOT-ov25 trial","volume":"34","author":"Ray-Coquard","year":"2023","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.eclinm.2026.103895_bib134","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1016\/j.apsb.2024.01.009","article-title":"Bispecific antibody drug conjugates: making 1+1>2","volume":"14","author":"Gu","year":"2024","journal-title":"Acta Pharm Sin B"},{"issue":"8_Suppl_1","key":"10.1016\/j.eclinm.2026.103895_bib135","article-title":"Characterizing spatial expression patterns and prevalence of folate receptor alpha in relation to other existing and emerging ovarian cancer biomarkers [abstract]","volume":"85","author":"Themeles","year":"2025","journal-title":"Proc Am Assoc Cancer Res Annu Meet"},{"issue":"10","key":"10.1016\/j.eclinm.2026.103895_bib136","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1158\/1078-0432.CCR-21-3656","article-title":"Praluzatamab ravtansine, a CD166-Targeting antibody-drug conjugate, in patients with advanced solid tumors: an open-label phase I\/II trial","volume":"28","author":"Boni","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eclinm.2026.103895_bib137","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1200\/JCO.2023.41.16_suppl.2538","article-title":"A phase 1\/2 study of a first-in-human immune-stimulating antibody conjugate (ISAC) BDC-1001 in patients with advanced HER2-expressing solid tumors","volume":"41","author":"Li","year":"2023","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.eclinm.2026.103895_bib138","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/d41573-025-00121-y","article-title":"Dual-payload ADCs move into first oncology clinical trials","volume":"24","author":"Mullard","year":"2025","journal-title":"Nat Rev Drug Discov"},{"issue":"Abstract 1586","key":"10.1016\/j.eclinm.2026.103895_bib139","article-title":"KH815, a novel dual-payload TROP2-directed antibody-drug conjugate, shows potent antitumor efficacy in pre-clinical tumor model","volume":"85","author":"Zhao","year":"2025","journal-title":"Cancer Res"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537026001434?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537026001434?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T05:48:36Z","timestamp":1793944116000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537026001434"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":139,"alternative-id":["S2589537026001434"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2026.103895","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antibody drug conjugates in gynaecological cancers: navigating between opportunities and challenges","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2026.103895","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2026.103869","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2026.103890","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103895"}}